Tarsus Pharmaceuticals, Inc. based in Irvine, California, disclosed on August 6, 2026, that they have finalized a securities purchase agreement with selected qualified institutional buyers and accredited investors for a private investment in public equity (PIPE) financing. This agreement is anticipated to generate roughly $125.0 million in gross proceeds. Once placement agent fees and private placement expenses are deducted, the net proceeds are expected to differ.
